BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a
French company specializing in the development and manufacturing of
medical devices and smart drug delivery systems, and AgaMatrix, a
developer and manufacturer of novel solutions for blood glucose
monitoring, announce today that they have reached an agreement including
binding terms for distribution in the US and European markets and
co-development activities to be finalized with definitive agreements in
the next 3-5 months.
The two companies operate to improve compliance for diabetic patients
and decided to join their efforts for providing a unique solution on the
BIOCORP designs, develops and manufactures Mallya® (formerly
known with the project name Easylog), the add-on fitting insulin pen
injectors that captures key treatment information (selected dose, date
and time of injection) and transmits it to a dedicated mobile app.
On one hand, AgaMatrix gets non-exclusive rights to distribute Mallya®
in the US, the UK and the EU market in the diabetes field. And BIOCORP
also grants AgaMatrix exclusive rights to license and distribute the
device in the US white label market.
On the other hand, BIOCORP and AgaMatrix have co-development projects to
offer a breakthrough innovation combining AgaMatrix and BIOCORP
“The opportunity with AgaMatrix to bring Mallya on the US and
European markets is very promising and a key milestone in our strategy.
Beyond that, collaborating on a specific solution together with
AgaMatrix continues to position BIOCORP at the forefront of innovation
and providing the most effective solution for the benefits of patients,”
said Eric Dessertenne, COO of BIOCORP.
BIOCORP estimates that this contract could generate as much as 20M Euros
of revenue over the next five years and will disclose more precise
information and estimates in the future as the product is planned to
officially reach the market in 2019*.
* These forward-looking statements are not
guarantees of future performance and reliance should not be placed on
them. Such forward-looking statements necessarily involve known and
unknown risks and uncertainties, which may cause actual performance and
financial results to differ materially from any projections of future
performance or result expressed or implied by these forward-looking
ABOUT AGAMATRIX, Inc.
AgaMatrix, Inc. is a developer of diagnostic
technologies for glucose monitoring and wholly owned subsidiary of
AgaMatrix Holdings LLC. Based in New Hampshire, USA, AgaMatrix develops,
manufactures and markets innovative solutions for blood glucose
monitoring and data management on mobile and cloud platforms. AgaMatrix
has sold over 8 million blood glucose monitors and over 3 billion test
strips since the Company’s 2001 inception. For more information, please
Founded in 2004 in Issoire (near Clermont-Ferrand),
France, BIOCORP is a French company specializing in the development and
manufacturing of medical devices and innovative drug delivery systems.
It is listed as ‘Innovative Company’ by the French public investment
bank Bpifrance. With over fourteen years of experience and more than 30
manufactured products, BIOCORP is a key player in the industry,
providing drug delivery solutions that meet the evolving needs of
patients. Today, BIOCORP continues to innovate in medical plastics, its
core business, and to market traditional devices (alternative to
aluminum capsules, syringe and vial administration systems) that have
been an important source of recurring income. Its solid expertise and
capacity to innovate have allowed the company to develop new
Internet-connected products, including Mallya, a smart cap for pen
injectors that captures injection data and automatically transmits data
to a mobile app, helping patients to manage their treatment. The company
has a team of 45 employees. BIOCORP is listed on Euronext since July
2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20190218005114/en/